SMALL CELL LUNG CANCER (SCLC)

This study tests a new type of immune cell therapy called CAR-NK cells, which are designed to target multiple markers on small cell lung cancer cells. The trial includes 60 adults whose cancer has returned or not responded to at least one prior treatment. Participants will receiv…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This early-stage trial is testing a new drug called IBI115, alone or with other treatments, in 150 people with advanced small cell lung cancer. The main goals are to check safety, find the right dose, and see if it helps control the cancer. Participants will receive the drug for …

This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…

This study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …

This study tests a new drug called peluntamig (PT217) in people with advanced neuroendocrine cancers, such as small cell lung cancer, that have a specific protein called DLL3. The drug is given alone or with chemotherapy or immunotherapy. The trial aims to find the safest dose an…

This study tests an experimental drug called CP-383 in 150 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if CP-383 can slow or stop cancer growth and to find the safest and most effective dose. Participants take the drug dail…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer, a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions, then co…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and attack cancer cells that have a protein called PD-L1 on their surface. The study will involve about 30 adults with advanced solid tumors (like lung, breast, …

This early-phase trial is testing whether combining two drugs, lurbinectedin and osimertinib, is safe and effective for people with a rare type of lung cancer called transformed small cell lung cancer. The study plans to enroll 16 adults whose cancer has changed from a common for…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This study tests an experimental oral drug, VMD-928, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. Ab…

This study looks at how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer in everyday medical practice. Researchers will track 500 patients to see side effects, survival time, and how long the cancer stays under control. The goal i…

This early-stage trial tests the safety and best dose of a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to find the highest safe dose and check for side effects. Participants mus…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy after surgery can help keep small cell lung cancer from coming back. About 65 adults who had their lung cancer completely removed will receive this combination. The goal is to see if this …

This early-phase trial tests a new treatment called TC-D101 for people with a specific type of advanced small cell lung cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified to attack cancer cells carrying a protein calle…

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread widely. About 550 participants will receive the drug combo or a standard treatment to see which works better…

This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, w…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment …

This study is testing a new radioactive probe called PFD3 to see if it can improve the detection and assessment of small cell lung cancer (SCLC) using PET/CT scans. About 30 adults with SCLC will receive the probe and be monitored for side effects and imaging accuracy. The goal i…

This study is watching how lung cancer patients do when they get the drug tislelizumab in normal doctor visits, not in a strict research setting. About 240 people with small cell or non-small cell lung cancer will take part. The goal is to see how long they live, how the drug aff…

This study is gathering detailed information from 500 people with small cell lung cancer to learn how to tailor treatments like radiation and immunotherapy to each patient. The goal is to find the best timing and doses of radiotherapy to work with immunotherapy, improving outcome…